Trump’s FDA Chief Dr. Marty Makary Slams Medical Dogma in Healthcare
What this video covers
A two-hour Dad Saves America conversation with host John, published days after Makary’s confirmation as FDA commissioner — though the discussion itself is a Blind Spots book interview, with Makary speaking as a Johns Hopkins surgeon and author rather than about agency business. It ranges across his signature themes: collapsed public trust, COVID-era groupthink, hormone therapy, opioids, the microbiome, antibiotics and C-sections, peanut allergies, and hospital price gouging.
Key points
- On trust, Makary cites public trust in the medical establishment at about 40%, lowest among 25-to-40-year-olds. He calls the COVID response “a giant catastrophe” — toddler masking, school closures, booster recommendations for healthy children — and says officials told him privately that natural immunity was ignored because acknowledging it might create vaccine hesitancy. He also argues an “illusion of consensus” was manufactured at the top, and that the US outcome was almost twice as bad as Sweden’s.
- On hormone replacement therapy, Makary says women who start HRT within ten years of menopause live on average three and a half years longer, with heart attacks cut in half, cognitive decline down 50 to 60%, and Alzheimer’s risk down 35% in one major observational study. He says roughly 90% of doctors still will not recommend it because of the 2002 Women’s Health Initiative announcement — a breast-cancer finding he investigated and says was never statistically significant.
- On opioids, Makary traces the “not addictive” dogma to a short 1980 New England Journal of Medicine letter based on hospitalized patients. He admits that as a resident he “gave out opioids like candy,” including 90-pill prescriptions, and says his research team later derived post-surgery guidelines at a third to a quarter of common practice; he cites a University of Michigan study finding one in six minor-surgery patients still taking opioids at three months. He says Purdue Pharma deserves blame but “we all have a piece of the pie.”
- On the microbiome, Makary calls a Mayo Clinic study of roughly 10,000 children the most significant study of the last decade: early antibiotic exposure was associated with obesity, learning disabilities, ADHD and asthma, and celiac disease nearly 300% higher, with a dose-dependent pattern; he notes a Danish study of about a million children found similar results, and that farmers have long used antibiotics to fatten livestock.
- On childbirth, Makary says antibiotics and C-sections are both massively overused and both alter the microbiome; he cites a JAMA Surgery study associating C-section birth with colon cancer before age 50, criticizes the “a C-section might be safer for the baby” nudge, and recalls that in the 1950s and 60s newborns were routinely separated from their mothers for about ten days.
- On peanut allergies, Makary says the American Academy of Pediatrics’ 2000 recommendation of total peanut avoidance for children ages 0–3 “got it perfectly backwards,” sensitizing the immune systems it meant to protect; he cites New England Journal of Medicine follow-ups showing more than eight-fold higher allergy rates with avoidance. He broadens the point into a critique of medicalizing childhood — anxiety labels for normal emotions, six-year-olds put on Ozempic, and CDC school suicide-awareness posters he considers harmful.
- On prices, Makary traces the hospital price-transparency executive order to his book The Price We Pay; he describes his JAMA study finding that about a third of hospitals sued patients — often low-income Walmart, food-service and postal workers — and how he and his students helped defendants get cases dismissed for lack of a valid contract. He also notes the American Medical Association profits from licensing the billing code book every provider must use.
- On the system overall, Makary describes an “arms race” in which hospitals and insurers exploit non-transparent prices and third-party payment; he estimates most businesses overpay 20 to 25% on health benefits through PBM spread pricing and rebates, and says his research team calculates that about half of federal spending goes to health care in its many forms.